142 related articles for article (PubMed ID: 28065783)
1. Mathematical modeling of mutant transferrin-CRM107 molecular conjugates for cancer therapy.
Yoon DJ; Chen KY; Lopes AM; Pan AA; Shiloach J; Mason AB; Kamei DT
J Theor Biol; 2017 Mar; 416():88-98. PubMed ID: 28065783
[TBL] [Abstract][Full Text] [Related]
2. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas.
Weaver M; Laske DW
J Neurooncol; 2003 Oct; 65(1):3-13. PubMed ID: 14649881
[TBL] [Abstract][Full Text] [Related]
3. Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins.
Yoon DJ; Chu DS; Ng CW; Pham EA; Mason AB; Hudson DM; Smith VC; MacGillivray RT; Kamei DT
J Control Release; 2009 Feb; 133(3):178-84. PubMed ID: 18992290
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of transferrin iron release increases in vitro drug carrier efficacy.
Lao BJ; Tsai WL; Mashayekhi F; Pham EA; Mason AB; Kamei DT
J Control Release; 2007 Feb; 117(3):403-12. PubMed ID: 17239470
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice.
Laske DW; Ilercil O; Akbasak A; Youle RJ; Oldfield EH
J Neurosurg; 1994 Mar; 80(3):520-6. PubMed ID: 8113865
[TBL] [Abstract][Full Text] [Related]
6. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107.
Hagihara N; Walbridge S; Olson AW; Oldfield EH; Youle RJ
Cancer Res; 2000 Jan; 60(2):230-4. PubMed ID: 10667564
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of protein synthesis inhibition and recovery in CRM107 immunotoxin-treated HeLa cells.
Wenning LA; Yazdi PT; Murphy RM
Biotechnol Bioeng; 1998 Feb; 57(4):484-96. PubMed ID: 10099226
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.
Yoon DJ; Kwan BH; Chao FC; Nicolaides TP; Phillips JJ; Lam GY; Mason AB; Weiss WA; Kamei DT
Cancer Res; 2010 Jun; 70(11):4520-7. PubMed ID: 20460527
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors.
Laske DW; Youle RJ; Oldfield EH
Nat Med; 1997 Dec; 3(12):1362-8. PubMed ID: 9396606
[TBL] [Abstract][Full Text] [Related]
10. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.
Tortorella S; Karagiannis TC
J Membr Biol; 2014 Apr; 247(4):291-307. PubMed ID: 24573305
[TBL] [Abstract][Full Text] [Related]
11. Diphtheria toxin mutant selectively kills cerebellar Purkinje neurons.
Riedel CJ; Muraszko KM; Youle RJ
Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5051-5. PubMed ID: 2367523
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of protein synthesis inhibition by transferrin-toxin conjugates.
Yazdi PT; Murphy RM
Cancer Res; 1994 Dec; 54(24):6387-94. PubMed ID: 7987833
[TBL] [Abstract][Full Text] [Related]
13. Improving the systemic drug delivery efficacy of nanoparticles using a transferrin variant for targeting.
Chiu RY; Tsuji T; Wang SJ; Wang J; Liu CT; Kamei DT
J Control Release; 2014 Apr; 180():33-41. PubMed ID: 24524898
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
15. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.
Wenning LA; Murphy RM
Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565
[TBL] [Abstract][Full Text] [Related]
16. Transferrin-oligomers as potential carriers in anticancer drug delivery.
Lim CJ; Shen WC
Pharm Res; 2004 Nov; 21(11):1985-92. PubMed ID: 15587919
[TBL] [Abstract][Full Text] [Related]
17. Engineered Polymer-Transferrin Conjugates as Self-Assembling Targeted Drug Delivery Systems.
Makwana H; Mastrotto F; Magnusson JP; Sleep D; Hay J; Nicholls KJ; Allen S; Alexander C
Biomacromolecules; 2017 May; 18(5):1532-1543. PubMed ID: 28350442
[TBL] [Abstract][Full Text] [Related]
18. Intracellular targeting with low pH-triggered bispecific antibodies.
Raso V; Brown M; McGrath J
J Biol Chem; 1997 Oct; 272(44):27623-8. PubMed ID: 9346900
[TBL] [Abstract][Full Text] [Related]
19. Diphtheria toxin-based targeted toxin therapy for brain tumors.
Li YM; Vallera DA; Hall WA
J Neurooncol; 2013 Sep; 114(2):155-64. PubMed ID: 23695514
[TBL] [Abstract][Full Text] [Related]
20. The targeted delivery of doxorubicin with transferrin-conjugated block copolypeptide vesicles.
Lee BS; Yip AT; Thach AV; Rodriguez AR; Deming TJ; Kamei DT
Int J Pharm; 2015 Dec; 496(2):903-11. PubMed ID: 26456252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
